51 related articles for article (PubMed ID: 8838865)
1. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity.
Dumont JA; Bitonti AJ; Wallace CD; Baumann RJ; Cashman EA; Cross-Doersen DE
Cell Growth Differ; 1996 Mar; 7(3):351-9. PubMed ID: 8838865
[TBL] [Abstract][Full Text] [Related]
2. Altered radiation responses of breast cancer cells resistant to hormonal therapy.
Luzhna L; Lykkesfeldt AE; Kovalchuk O
Oncotarget; 2015 Jan; 6(3):1678-94. PubMed ID: 25682200
[TBL] [Abstract][Full Text] [Related]
3. Expression of Q227L-galphas in MCF-7 human breast cancer cells inhibits tumorigenesis.
Chen J; Bander JA; Santore TA; Chen Y; Ram PT; Smit MJ; Iyengar R
Proc Natl Acad Sci U S A; 1998 Mar; 95(5):2648-52. PubMed ID: 9482941
[TBL] [Abstract][Full Text] [Related]
4. Dynamic interactions between the extracellular matrix and estrogen activity in progression of ER+ breast cancer.
Jallow F; O'Leary KA; Rugowski DE; Guerrero JF; Ponik SM; Schuler LA
Oncogene; 2019 Oct; 38(43):6913-6925. PubMed ID: 31406251
[TBL] [Abstract][Full Text] [Related]
5. Adhesion in Physiological, Benign and Malignant Proliferative States of the Endometrium: Microenvironment and the Clinical Big Picture.
Rutherford EJ; Hill ADK; Hopkins AM
Cells; 2018 May; 7(5):. PubMed ID: 29772648
[TBL] [Abstract][Full Text] [Related]
6. KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function.
Gala K; Li Q; Sinha A; Razavi P; Dorso M; Sanchez-Vega F; Chung YR; Hendrickson R; Hsieh JJ; Berger M; Schultz N; Pastore A; Abdel-Wahab O; Chandarlapaty S
Oncogene; 2018 Aug; 37(34):4692-4710. PubMed ID: 29755131
[TBL] [Abstract][Full Text] [Related]
7. Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance.
Malorni L; Giuliano M; Migliaccio I; Wang T; Creighton CJ; Lupien M; Fu X; Hilsenbeck SG; Healy N; De Angelis C; Mazumdar A; Trivedi MV; Massarweh S; Gutierrez C; De Placido S; Jeselsohn R; Brown M; Brown PH; Osborne CK; Schiff R
Mol Cancer Res; 2016 May; 14(5):470-81. PubMed ID: 26965145
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.
García-Becerra R; Santos N; Díaz L; Camacho J
Int J Mol Sci; 2012 Dec; 14(1):108-45. PubMed ID: 23344024
[TBL] [Abstract][Full Text] [Related]
9. Differential gene expression in tamoxifen-resistant breast cancer cells revealed by a new analytical model of RNA-Seq data.
Huber-Keener KJ; Liu X; Wang Z; Wang Y; Freeman W; Wu S; Planas-Silva MD; Ren X; Cheng Y; Zhang Y; Vrana K; Liu CG; Yang JM; Wu R
PLoS One; 2012; 7(7):e41333. PubMed ID: 22844461
[TBL] [Abstract][Full Text] [Related]
10. Macrophage-elicited loss of estrogen receptor-α in breast cancer cells via involvement of MAPK and c-Jun at the ESR1 genomic locus.
Stossi F; Madak-Erdoğan Z; Katzenellenbogen BS
Oncogene; 2012 Apr; 31(14):1825-34. PubMed ID: 21860415
[TBL] [Abstract][Full Text] [Related]
11. Integrated quantitative analysis of the phosphoproteome and transcriptome in tamoxifen-resistant breast cancer.
Oyama M; Nagashima T; Suzuki T; Kozuka-Hata H; Yumoto N; Shiraishi Y; Ikeda K; Kuroki Y; Gotoh N; Ishida T; Inoue S; Kitano H; Okada-Hatakeyama M
J Biol Chem; 2011 Jan; 286(1):818-29. PubMed ID: 21044952
[TBL] [Abstract][Full Text] [Related]
12. Estradiol-induced regression in T47D:A18/PKCalpha tumors requires the estrogen receptor and interaction with the extracellular matrix.
Zhang Y; Zhao H; Asztalos S; Chisamore M; Sitabkhan Y; Tonetti DA
Mol Cancer Res; 2009 Apr; 7(4):498-510. PubMed ID: 19372579
[TBL] [Abstract][Full Text] [Related]
13. ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer.
Riggins RB; Lan JP; Zhu Y; Klimach U; Zwart A; Cavalli LR; Haddad BR; Chen L; Gong T; Xuan J; Ethier SP; Clarke R
Cancer Res; 2008 Nov; 68(21):8908-17. PubMed ID: 18974135
[TBL] [Abstract][Full Text] [Related]
14. Oral administration of blueberry inhibits angiogenic tumor growth and enhances survival of mice with endothelial cell neoplasm.
Gordillo G; Fang H; Khanna S; Harper J; Phillips G; Sen CK
Antioxid Redox Signal; 2009 Jan; 11(1):47-58. PubMed ID: 18817478
[TBL] [Abstract][Full Text] [Related]
15. Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways.
Safe S; Kim K
J Mol Endocrinol; 2008 Nov; 41(5):263-75. PubMed ID: 18772268
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen resistance and epigenetic modifications in breast cancer cell lines.
Badia E; Oliva J; Balaguer P; Cavaillès V
Curr Med Chem; 2007; 14(28):3035-45. PubMed ID: 18220739
[TBL] [Abstract][Full Text] [Related]
17. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer.
Zhou Y; Yau C; Gray JW; Chew K; Dairkee SH; Moore DH; Eppenberger U; Eppenberger-Castori S; Benz CC
BMC Cancer; 2007 Apr; 7():59. PubMed ID: 17407600
[TBL] [Abstract][Full Text] [Related]
18. Elevated protein kinase C alpha expression may be predictive of tamoxifen treatment failure.
Tonetti DA; Morrow M; Kidwai N; Gupta A; Badve S
Br J Cancer; 2003 May; 88(9):1400-2. PubMed ID: 12778068
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention of breast cancer: implications for postmenopausal women.
Fabian CJ; Kimler BF
Drugs Aging; 2002; 19(1):43-78. PubMed ID: 11929326
[TBL] [Abstract][Full Text] [Related]
20. Demonstration of estrogen receptors and of estrogen responsiveness in the HKT-1097 cell line derived from diethylstilbestrol-induced kidney tumors.
Brohée R; Nonclercq D; Journé DN; Toubeau G; Falmagne P; Leclercq G; Heuson-Stiennon JA; Laurent G
In Vitro Cell Dev Biol Anim; 2000; 36(10):640-9. PubMed ID: 11229596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
